<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2023.1199751</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Glycolytic reprogramming in macrophages and MSCs during inflammation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Xueping</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn004">
<sup>&#x2021;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1117306"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shen</surname>
<given-names>Huaishuang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn004">
<sup>&#x2021;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1123540"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Mao</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1490054"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Teissier</surname>
<given-names>Victoria</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1851149"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Ejun Elijah</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Qi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1038687"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tsubosaka</surname>
<given-names>Masanori</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1920084"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Toya</surname>
<given-names>Masakazu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1875604"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kushioka</surname>
<given-names>Junichi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1535227"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maduka</surname>
<given-names>Chima V.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2269936"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Contag</surname>
<given-names>Christopher H.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2222850"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chow</surname>
<given-names>Simon Kwoon-Ho</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2342945"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhang</surname>
<given-names>Ning</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/994210"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Goodman</surname>
<given-names>Stuart B.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/764324"/>
</contrib>
</contrib-group>    <aff id="aff1">
<sup>1</sup>
<institution>Department of Orthopaedic Surgery, Stanford University School of Medicine</institution>, <addr-line>Stanford, CA</addr-line>, <country>United States</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Orthopaedic Surgery, First Affiliated Hospital of Soochow University</institution>, <addr-line>Suzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Cardiovascular Institute Operations, Stanford University School of Medicine</institution>, <addr-line>Stanford, CA</addr-line>, <country>United States</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Departments of Biomedical Engineering and Microbiology &amp; Molecular Genetics, Michigan State University</institution>, <addr-line>East Lansing, MI</addr-line>, <country>United States</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Institute for Quantitative Health Science and Engineering, Michigan State University</institution>, <addr-line>East Lansing, MI</addr-line>, <country>United States</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong</institution>, <addr-line>Hong Kong</addr-line>, <country>Hong Kong SAR, China</country>
</aff>
<aff id="aff7">
<sup>7</sup>
<institution>Department of Bioengineering, Stanford University</institution>, <addr-line>Stanford, CA</addr-line>, <country>United States</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Bowen Wu, Zhejiang University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Weiqian Chen, Zhejiang University, China; Duygu Sag, Dokuz Eylul University, T&#xfc;rkiye</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Ning Zhang, <email xlink:href="mailto:ningzhang@cuhk.edu.hk">ningzhang@cuhk.edu.hk</email>; Stuart B. Goodman, <email xlink:href="mailto:goodbone@stanford.edu">goodbone@stanford.edu</email>
</p>
</fn>
<fn fn-type="present-address" id="fn003">
<p>&#x2020;Present address: Chima V. Maduka, Burdick Lab, BioFrontiers Institute | Chemical &amp; Biological Engineering University of Colorado, Boulder, CO, United States</p>
</fn>
<fn fn-type="equal" id="fn004">
<p>&#x2021;These authors have contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>08</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1199751</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>04</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>07</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Li, Shen, Zhang, Teissier, Huang, Gao, Tsubosaka, Toya, Kushioka, Maduka, Contag, Chow, Zhang and Goodman</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Li, Shen, Zhang, Teissier, Huang, Gao, Tsubosaka, Toya, Kushioka, Maduka, Contag, Chow, Zhang and Goodman</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Dysregulated inflammation is associated with many skeletal diseases and disorders, such as osteolysis, non-union of fractures, osteonecrosis, osteoarthritis and orthopaedic infections. We previously showed that continuous infusion of lipopolysaccharide (LPS) contaminated polyethylene particles (cPE) caused prolonged inflammation and impaired bone formation. However, the metabolic and bioenergetic processes associated with inflammation of bone are unknown. Mitochondria are highly dynamic organelles that modulate cell metabolism and orchestrate the inflammatory responses that involve both resident and recruited cells. Glycolytic reprogramming, the shift from oxidative phosphorylation (OXPHOS) to glycolysis causes inappropriate cell activation and function, resulting in dysfunctional cellular metabolism. We hypothesized that impaired immunoregulation and bone regeneration from inflammatory states are associated with glycolytic reprogramming and mitochondrial dysfunction in macrophages (M&#x3c6;) and mesenchymal stromal cells (MSCs).</p>
</sec>
<sec>
<title>Methods</title>
<p>We used the Seahorse XF96 analyzer and real-time qPCR to study the bioenergetics of M&#x3c6; and MSCs exposed to cPE. To understand the oxygen consumption rate (OCR), we used Seahorse XF Cell Mito Stress Test Kit with Seahorse XF96 analyzer. Similarly, Seahorse XF Glycolytic Rate Assay Kit was used to detect the extracellular acidification rate (ECAR) and Seahorse XF Real-Time ATP Rate Assay kit was used to detect the real-time ATP production rates from OXPHOS and glycolysis. Real-time qPCR was performed to analyze the gene expression of key enzymes in glycolysis and mitochondrial biogenesis. We further detected the gene expression of proinflammatory cytokines in M&#x3c6; and genes related to cell differentiation in MSC during the challenge of cPE.</p>
</sec>
<sec>
<title>Results</title>
<p>Our results demonstrated that the oxidative phosphorylation of M&#x3c6; exposed to cPE was significantly decreased when compared with the control group. We found reduced basal, maximal and ATP-production coupled respiration rates, and decreased proton leak in M&#x3c6; during challenge with cPE. Meanwhile, M&#x3c6; showed increased basal glycolysis and proton efflux rates (PER) when exposed to cPE. The percentage (%) of PER from glycolysis was higher in M&#x3c6; exposed to cPE, indicating that the contribution of the glycolytic pathway to total extracellular acidification was elevated during the challenge of cPE. In line with the results of OCR and ECAR, we found M&#x3c6; during cPE challenge showed higher glycolytic ATP (glycoATP) production rates and lower mitochondrial ATP (mitoATP) production rates which is mainly from OXPHOS. Interestingly, MSCs showed enhanced glycolysis during challenge with cPE, but no significant changes in oxygen consumption rates (OCR). In accordance, seahorse assay of real-time ATP revealed glycoATP rates were elevated while mitoATP rates showed no significant differences in MSC during challenge with cPE. Furthermore, M&#x3c6; and MSCs exposed to cPE showed upregulated gene expression levels of glycolytic regulators and M&#x3c6; exposed to cPE expressed higher levels of pro-inflammatory cytokines.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>This study demonstrated the dysfunctional bioenergetic activity of bone marrow-derived M&#x3c6; and MSCs exposed to cPE, which could impair the immunoregulatory properties of cells in the bone niche. The underlying molecular defect related to disordered mitochondrial function could represent a potential therapeutic target during the resolution of inflammation.</p>
</sec>
</abstract>
<kwd-group>
<kwd>inflammation</kwd>
<kwd>mitochondrial bioenergetics</kwd>
<kwd>bone marrow-derived cells</kwd>
<kwd>macrophage</kwd>
<kwd>mesenchymal stromal cell</kwd>
</kwd-group>    <contract-num rid="cn001">R01AR073145, R01AR063717</contract-num>    <contract-sponsor id="cn001">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content>
</contract-sponsor>    <contract-sponsor id="cn002">Stanford University<named-content content-type="fundref-id">10.13039/100005492</named-content>
</contract-sponsor>
<counts>
<fig-count count="9"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="72"/>
<page-count count="14"/>
<word-count count="5944"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Molecular Innate Immunity</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Bone tissue regeneration undergoes three continuing and overlapping phases: inflammation, regeneration, and remodeling (<xref ref-type="bibr" rid="B1">1</xref>). While the inflammatory process is crucial for tissue repair, dysregulated inflammation, including either decreased or elevated levels, is detrimental to bone healing (<xref ref-type="bibr" rid="B2">2</xref>&#x2013;<xref ref-type="bibr" rid="B4">4</xref>). Consequences of altered bone homeostasis due to dysregulated inflammation include progressive bone loss (<xref ref-type="bibr" rid="B5">5</xref>), impairment of bone formation and subsequent fracture healing (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>), implant-related osteolysis (<xref ref-type="bibr" rid="B8">8</xref>&#x2013;<xref ref-type="bibr" rid="B10">10</xref>) and other problems.</p>
<p>Mitochondria are highly dynamic organelles that are responsible for the cell&#x2019;s energy production and metabolism; they are capable of responding to the local cellular microenvironment and alter energy production and coordinate the inflammatory response of both resident and recruited cells (<xref ref-type="bibr" rid="B11">11</xref>). Glycolytic reprogramming is the shift from oxidative phosphorylation (OXPHOS) to glycolysis and is observed in various immune cells including macrophages (M&#x3c6;), dendritic cells, T-cells and neutrophils (<xref ref-type="bibr" rid="B12">12</xref>). This phenomenon is also observed in the activation of M&#x3c6; during inflammatory responses (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). Pro-inflammatory M&#x3c6; demonstrate a higher level of glycolytic production of adenosine triphosphate (ATP) associated with increased production of proinflammatory cytokines including tumor necrosis factor-alpha (TNF-&#x3b1;), interleukin-1-beta (IL-1&#x3b2;), monocyte chemoattractant protein-1 (MCP-1); anti-inflammatory M&#x3c6; show a higher level of oxidative phosphorylation (OXPHOS) associated with increased secretion of anti-inflammatory cytokines such as IL-4 or IL-10. The shift in the bioenergetic pathway causes a shift in cell activation and function, resulting in a vicious cycle of disrupted cellular metabolism in the local tissues including bone (<xref ref-type="bibr" rid="B15">15</xref>) or muscle (<xref ref-type="bibr" rid="B16">16</xref>), hindering their homeostasis or regenerative potential.</p>
<p>Mesenchymal stem cells (MSCs) are multipotent non-hematopoietic cell precursors found in the bone marrow (<xref ref-type="bibr" rid="B17">17</xref>). MSCs are capable of self-renewal, multidirectional differentiation and immunoregulation, and their pluripotency makes them an ideal cell therapy for mesoderm-derived tissue regeneration and immune modulation (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>). Mitochondrial dynamics impact cell differentiation as well as immune function in MSCs (<xref ref-type="bibr" rid="B20">20</xref>). Upon osteogenic differentiation, quiescent MSCs changed their energy acquisition pathway from glycolysis to mitochondrial oxidative metabolism that generates energy through mitochondrial OXPHOS; mitochondrial dysfunction impairs this process (<xref ref-type="bibr" rid="B21">21</xref>&#x2013;<xref ref-type="bibr" rid="B23">23</xref>). In addition, MSCs adapt their energetic metabolism when acquiring immunomodulatory property and shift to glycolysis (<xref ref-type="bibr" rid="B24">24</xref>). The immunoregulatory effect of MSCs on macrophage polarization and Th17 switch is related to the glycolytic status of the MSCs. MSCs pretreated with oligomycin decreased the M1/M2 ratio, inhibited CD4 T cell proliferation, and prevented Th17 switch to Treg cells (<xref ref-type="bibr" rid="B25">25</xref>). However, the role of mitochondrial bioenergetics on the immune properties of M&#x3c6; and MSCs during inflammation remains unknown.</p>
<p>Continuous infusion of lipopolysaccharide (LPS) contaminated polyethylene particles (cPE) has been applied to study the field of periprosthetic osteolysis and also has become a validated model for chronic inflammatory bone destruction (<xref ref-type="bibr" rid="B26">26</xref>&#x2013;<xref ref-type="bibr" rid="B29">29</xref>). In order to investigate the underlying mechanisms of acute and chronic inflammatory osteolysis, we have established a cPE-induced inflammatory model using both <italic>in vitro</italic> and <italic>in vivo</italic> studies (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>). Previously, we have shown that cPE causes prolonged inflammation, and impaired bone formation and increased bone degradation (<xref ref-type="bibr" rid="B31">31</xref>). We have also shown that modulating the inflammatory status by injecting genetically modified MSCs that release the anti-inflammatory cytokine IL-4 in response to activation of the pro-inflammatory transcription factor NF-&#x3ba;B mitigated the above impairment in bone regeneration (<xref ref-type="bibr" rid="B32">32</xref>). In the current study, we used cPE to stimulate the early biological processes of the inflammatory reaction, similar to that seen to byproducts of total knee and hip arthroplasties, that eventually results in periprosthetic osteolysis. We hypothesized that inflammation would induce glycolytic reprogramming in M&#x3c6; and MSCs, associated with the release of pro-inflammatory cytokines. This <italic>in vitro</italic> study investigated changes in mitochondrial bioenergetics in bone marrow-derived M&#x3c6; and MSCs during challenge with cPE.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="s2_1">
<title>Preparation of ultra-high molecular weight polyethylene particles</title>
<p>Polyethylene particles were made as previously described (<xref ref-type="bibr" rid="B33">33</xref>). Briefly, after washed with pure ethanol, Ceridust 3610 polyethylene particles (Clariant Corporation, CA, United States) were filtered through a 20 &#x3bc;m pore membrane. In the Cell Sciences Imaging Facility at Stanford University, the filtered particle size was measured as 4.62 &#xb1; 3.76 &#x3bc;m with a scanning electron microscope (Zeiss Sigma FESEM, Zeiss Sigma, CA, United States). After vacuum dried for 3 days, particles were resuspended in 5% BSA/PBS. The approximate concentration was tested 3.1 &#xd7; 10<sup>10</sup> particles/ml, and the sterility was confirmed by Limulus Amebocyte Lysate assay (Lonza, Portsmouth, NH) (<xref ref-type="bibr" rid="B34">34</xref>).</p>
</sec>
<sec id="s2_2">
<title>Cell culture</title>
<p>Bone marrow-derived M&#x3c6; and MSCs were collected from C57BL/6J female mice aged 8-10 weeks old as previously described (<xref ref-type="bibr" rid="B35">35</xref>). Stanford Institutional Animal Care and Use Committee (IACUC) approved this isolation protocol (Protocol number: APLAC-9964) and institutional guidelines were followed and observed in all aspects. Briefly, femurs and tibias were digested under sterile conditions. Using a 25-gauge needle, the bone marrow was flushed and filtered (70 &#xb5;m) into a 50 mL centrifuge tube by injecting 5 mL of macrophage basal medium (RPMI Medium 1640 supplemented with 10% fetal bovine serum, 1% Antibiotic-Antimycotic (Invitrogen, Grand Island, NY)) or 5mL of MSC basal medium (MEM alpha, supplemented with 10% FBS, 1% antibiotic-antimycotic (Thermo Fisher Scientific, Waltham, MA, USA)). Cells were centrifuged at 400 g for 10 min and resuspended in 1-3 mL/tube of iced cold red blood cell lysis buffer (Invitrogen) for 2 minutes at 4&#xb0;C, followed by the addition of 20 mL/tube basal medium. Na&#xef;ve macrophages were differentiated in augmented macrophage basal medium (RPMI supplemented with 10% Heat-Inactivated FBS, 1% antibiotic-antimycotic, 30% L929 conditioned medium (LCM) and 100 ng/mL M-CSF (R&amp;D Systems, Minneapolis, MN, USA)) for 7 days (<xref ref-type="bibr" rid="B36">36</xref>). The attached M&#x3c6; were digested with trypsin and scraped off for further culturing or cryopreserved at -80 &#xb0;C. For MSCs, cells were cultured and purified with MSC basal medium into T175 flasks until passage 6 before they were cryopreserved at -80 &#xb0;C.</p>
<p>M&#x3c6; were seeded in the augmented basal medium in 24-well plates at a concentration of 5 x 10<sup>5</sup> cells/mL with macrophage augmented basal medium with or without cPE (0.125% polyethylene particles coated added with 10 ng/ml Lipopolysaccharides (LPS, Sigma-Aldrich St Louis, MO) in 10% BSA/PBS) (<xref ref-type="bibr" rid="B37">37</xref>).</p>
<p>P8-P10 MSCs were seeded in the basal medium in 24-well plates at a concentration of 1 x 10<sup>5</sup> cells/mL overnight for attachment. Then cells were washed and cultured with osteogenic differentiation medium (&#x3b1;-MEM supplemented with 10% &#x3b2;-glycerophosphate, 50 mM ascorbic acid, 100 mM Vitamin D3, and 100 nM dexamethasone) with or without cPE. Both M&#x3c6; and MSCs samples were harvested for analysis at 4 timepoints, 0, 6, 24 and 48 hours (n = 3 per condition and per timepoint) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Schematic diagram of experimental design. Bone marrow-derived M&#x3c6; and MSCs were collected respectively. Cells were cultured with certain mediums for M&#x3c6; stimulation or MSC osteogenic differentiation, with or without cPE challenge. Mitochondrial bioenergetics and genes of proinflammatory cytokines were analyzed at 6, 24 and 48 hours.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1199751-g001.tif"/>
</fig>
</sec>
<sec id="s2_3">
<title>RNA extraction, cDNA synthesis and quantitative real-time PCR (qRT-PCR)</title>
<p>Cells from each well were lysed and collected separately using TRIzol reagent. RNA was extracted with miRNeasy kit (Qiagen, mat. No. 1071023). Purity was measured with NanoDrop One (Thermo Fisher Scientific, Waltham, MA, USA). Reverse transcribed cDNA was made by the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystem, 4368814).</p>
<p>For quantitative real-time PCR, a reaction mix was prepared containing sample cDNA, primers, TaqMan primer-probes and TaqMan Gene Expression Master Mix (all from Applied Biosystems). Then qRT-PCR was performed on ABI 7900HT Sequencing Detection System (Applied Biosystems).</p>
<p>Primer sequences are summarized in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>, and &#x3b2;-actin was applied as in internal reference. The relative expression of target genes was calculated by the 2<sup>&#x2212;&#x394;&#x394;Ct</sup> method. All PCR reactions were conducted in triplicate.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Primer sequences used in this study.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Gene name</th>
<th valign="middle" align="left">Primer name</th>
<th valign="middle" align="left">Primer sequence (5&#xb4; to 3&#xb4;)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" rowspan="2" align="left">
<italic>Tnf-&#x3b1;</italic>
</td>
<td valign="middle" align="left">Mouse _ TNF-&#x3b1; _F</td>
<td valign="middle" align="left">TCTCATGCACCACCATCAAGGACT</td>
</tr>
<tr>
<td valign="middle" align="left">Mouse _ TNF-&#x3b1; _R</td>
<td valign="middle" align="left">ACCACTCTCCCTTTGCAGAACTCA</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">
<italic>Il-1&#x3b2;</italic>
</td>
<td valign="middle" align="left">Mouse_ Il-1&#x3b2; _F</td>
<td valign="middle" align="left">AAGGGCTGCTTCCAAACCTTTGAC</td>
</tr>
<tr>
<td valign="middle" align="left">Mouse_ <italic>Il-1&#x3b2;</italic> _R</td>
<td valign="middle" align="left">ATACTGCCTGCCTGAAGCTCTTGT</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">
<italic>Nos2</italic>
</td>
<td valign="middle" align="left">Mouse_ <italic>Nos2 _</italic>F</td>
<td valign="middle" align="left">TCTTTGACGCTCGGAACTGTAGCA</td>
</tr>
<tr>
<td valign="middle" align="left">Mouse_ <italic>Nos2</italic> _R</td>
<td valign="middle" align="left">ACCTGATGTTGCCATTGTTGGTGG</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">
<italic>Il-6</italic>
</td>
<td valign="middle" align="left">Mouse_ <italic>Il-6 _</italic>F</td>
<td valign="middle" align="left">ATCCAGTTGCCTTCTTGGGACTGA</td>
</tr>
<tr>
<td valign="middle" align="left">Mouse_ <italic>Il-6 _</italic>R</td>
<td valign="middle" align="left">TAAGCCTCCGACTTGTGAAGTGGT</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">
<italic>Fn1</italic>
</td>
<td valign="middle" align="left">Mouse _ <italic>Fn1 _</italic>F</td>
<td valign="middle" align="left">TGGTGGCCACTAAATACGAA</td>
</tr>
<tr>
<td valign="middle" align="left">Mouse _ <italic>Fn1 _</italic>R</td>
<td valign="middle" align="left">GGAGGGCTAACATTCTCCAG</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">
<italic>Runx2</italic>
</td>
<td valign="middle" align="left">Mouse _ <italic>Runx2 _</italic>F</td>
<td valign="middle" align="left">CTACCCAGCCACCTTTACCTAC</td>
</tr>
<tr>
<td valign="middle" align="left">Mouse _ <italic>Runx2 _</italic>R</td>
<td valign="middle" align="left">GAACTGATAGGATGCTGACGAAG</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">
<italic>Opn</italic>
</td>
<td valign="middle" align="left">Mouse _ <italic>Opn _</italic>F</td>
<td valign="middle" align="left">GACAACAACGGAAAGGGCAG</td>
</tr>
<tr>
<td valign="middle" align="left">Mouse _ <italic>Opn _</italic>R</td>
<td valign="middle" align="left">GATCGGCACTCTCCTGGCT</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">
<italic>Ocn</italic>
</td>
<td valign="middle" align="left">Mouse _ <italic>Ocn _</italic>F</td>
<td valign="middle" align="left">AGGAGGGCAATAAGGTAGTGAAC</td>
</tr>
<tr>
<td valign="middle" align="left">Mouse _ <italic>Ocn _</italic>R</td>
<td valign="middle" align="left">AGGCGGTCTTCAAGCCATAC</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">
<italic>Pfkfb3</italic>
</td>
<td valign="middle" align="left">Mouse _ <italic>Pfkfb3 _</italic>F</td>
<td valign="middle" align="left">AGAACTTCCACTCTCCCACCC</td>
</tr>
<tr>
<td valign="middle" align="left">Mouse _ <italic>Pfkfb3 _</italic>R</td>
<td valign="middle" align="left">AGGGTAGTGCCCATTGTTGAA</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">
<italic>Hif1&#x3b1;</italic>
</td>
<td valign="middle" align="left">Mouse _ <italic>Hif1&#x3b1; _</italic>F</td>
<td valign="middle" align="left">ACCTTCATCGGAAACTCC</td>
</tr>
<tr>
<td valign="middle" align="left">Mouse _ <italic>Hif1&#x3b1; _</italic>R</td>
<td valign="middle" align="left">CTGTTAGGCTGGGAAAAG</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">
<italic>Pgc-1&#x3b1;</italic>
</td>
<td valign="middle" align="left">Mouse _ <italic>Pgc-1&#x3b1; _</italic>F</td>
<td valign="middle" align="left">AAACTTGCTAGCGGTCCTCA</td>
</tr>
<tr>
<td valign="middle" align="left">Mouse _ <italic>Pgc-1&#x3b1; _</italic>R</td>
<td valign="middle" align="left">TGGCTGGTGCCAGTAAGAG</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2_4">
<title>Analysis of cell bioenergetics</title>
<p>The oxygen consumption rate (OCR), the extracellular acidification rate (ECAR) and Real-Time ATP rate were measured using a Seahorse XFe96 Analyzer (Agilent, California, CA, USA) with Seahorse XF Cell Mito Stress Test Kit (Agilent, cat#: 103015-100), Seahorse XF Glycolytic Rate Assay Kit (Agilent, cat#: 103344-100) and Seahorse XF Real-Time ATP Rate Assay kit (Agilent, cat#: 103592-100), respectively, following the manufacturer&#x2019;s instructions. Briefly, M&#x3c6; and MSCs were seeded in 96-well Seahorse assay plates at a concentration of 1.5 &#xd7; 10<sup>5</sup> or 5 &#xd7; 10<sup>4</sup> cells/well, respectively and cultured overnight for attachment. Prior to the assay, cells were washed, and the medium was replaced with Seahorse XF RPMI for M&#x3c6; or DMEM for MSCs supplemented with 20 mM glucose, 2 mM L-glutamine and 1 mM sodium pyruvate. M&#x3c6; and MSCs were tested separately after cPE culturing at multiple time points (6, 24 and 48 hours). Presto Blue&#x2122; assays (Thermo Fisher Scientific) were used to evaluate cell viability and normalize readings from the Seahorse XF Analyzer.</p>
</sec>
<sec id="s2_5">
<title>Statistical analysis</title>
<p>The statistical analysis was conducted using Prism 8 (GraphPad Software, San Diego, CA). Data were expressed as mean &#xb1; Standard error of mean (SEM). Two-tailed unpaired Student&#x2019;s t-test was used to compare data between groups. One-way ANOVA was used to detect differences within group between time-points. <italic>p</italic> &lt; 0.05 was regarded as statistically significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Reduced mitochondrial respiratory capacity in M&#x3c6; during challenge with cPE</title>
<p>To determine the functional changes in the cellular metabolic activity of M&#x3c6;, we first evaluated the oxygen consumption rate (OCR; a measure of oxidative phosphorylation) using the Seahorse XF Analyzer in conjunction with the XF mito stress kit, a measure of overall mitochondrial respiration capacity. The addition of 1.5 &#x3bc;M oligomycin, 1.5 &#x3bc;M FCCP, and 0.5 &#x3bc;M Rotenone/Antimycin A allowed us to evaluate the contribution and sources of both mitochondrial and nonmitochondrial oxygen consumption to our measured signal. <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref> shows the calculations that can be made with the addition of each substrate. The basal respiration rates of M&#x3c6; were decreased at 24 and 48 hours of co-incubation with cPE (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>). The increase of oxygen consumption after adding the uncoupling agent FCCP reflected the mitochondrial reserve function. After the addition of FCCP, the maximal respiration of M&#x3c6; exposed to cPE was significantly decreased compared with the control group without cPE from 24 to 48 hours (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>). In addition, compared to the control group, the ATP production coupled respiration rates and proton leakage rates were reduced with significant differences in M&#x3c6; at 24 and 48 hours of challenge with cPE (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2D, E</bold>
</xref>). Our results suggested that the oxidative phosphorylation of M&#x3c6; is defective after 24 hours of challenge with cPE.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Oxygen Consumption Rates (OCR) of M&#x3c6; during challenge with cPE. <bold>(A)</bold> OCR of macrophages were measured with or without cPE at various time points and normalized with cell numbers with consecutive injections of oligomycin (Oligo at 1.5 &#x3bc;M), FCCP (1.5 &#x3bc;M), and Rotenone/antimycin A (0.5 &#x3bc;M). <bold>(B&#x2013;E)</bold> Basal respiration, Maximal respiration, ATP-production coupled respiration and Proton leak rates were presented as bar graphs. Data are shown as mean &#xb1; SEM, <sup>*</sup>
<italic>p</italic> &lt; 0.05, <sup>**</sup>
<italic>p</italic> &lt; 0.01, <sup>***</sup>
<italic>p</italic> &lt; 0.001, n.s., no significance. two-tailed unpaired Student&#x2019;s t-tests were compared between control and cPE groups at each time point (n = 10 per each group); One-way ANOVA was used to detect differences within group between time-points.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1199751-g002.tif"/>
</fig>
</sec>
<sec id="s3_2">
<title>Increased glycolysis in M&#x3c6; during challenge with cPE</title>
<p>To further investigate the mitochondrial metabolism in M&#x3c6;, we next examined the extracellular acidification rates (ECAR; a measure of glycolysis) following sequential addition of compounds containing 0.5 &#x3bc;M Rotenone/Antimycin A (Rot/AA) and 50 mM 2-DG (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>). The data showed that the basal glycolysis, physiological rate, and proton efflux rates were significantly higher starting at 6 hours in M&#x3c6; exposed to cPE compared with the control groups (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3B, C</bold>
</xref>). <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3D</bold>
</xref> shows the percentage (%) of Proton Efflux Rate (PER) from glycolysis, representing the contribution of the glycolytic pathway to total extracellular acidification. The total rate of extracellular acidification is the sum of two components: respiratory acidification, in the form of CO<sub>2</sub> produced in the citric acid cycle, and anaerobic glycolytic acidification in the form of lactate<sup>-</sup> + H<sup>+</sup> (<xref ref-type="bibr" rid="B38">38</xref>). We found that the %PER from glycolysis were significantly higher in M&#x3c6; challenged with cPE (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3D</bold>
</xref>). When Rot/AA was added to inhibit mitochondrial respiration, cells were able to increase energy production <italic>via</italic> a compensatory increase in glycolysis. This compensatory increase in glycolysis of M&#x3c6; exposed to cPE was higher than the control groups at 6 hours and 48 hours (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3E</bold>
</xref>). In conclusion, cPE exposure promoted the glycolytic pathway while suppressing mitochondrial respiration in M&#x3c6;.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Extra Cellular Acidification Rates (ECAR) of M&#x3c6; during challenge with cPE. <bold>(A)</bold> ECAR of M&#x3c6; with or without cPE challenge at various time points followed by injections of Rot/AA (0.5 &#x3bc;M), and 2-DG (50 mM) were obtained. <bold>(B&#x2013;E)</bold> Basal glycolysis, Basal proton efflux rate, % PER from glycolysis and Compensatory glycolysis rates were presented as bar graphs. Data are shown as mean &#xb1; SEM, <sup>*</sup>
<italic>p</italic> &lt; 0.05, <sup>**</sup>
<italic>p</italic> &lt; 0.01, <sup>***</sup>
<italic>p</italic> &lt; 0.001, n.s., no significance. two-tailed unpaired Student&#x2019;s t-tests were compared between control and cPE groups at each time point (n =10 per each group); One-way ANOVA was used to detect differences within group between time-points.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1199751-g003.tif"/>
</fig>
</sec>
<sec id="s3_3">
<title>Increased production rates of glycoATP while reduced production rates of mitoATP in M&#x3c6; during challenge with cPE</title>
<p>Mitochondria play a central part in cellular energy production and mediate immunomodulatory signaling. The main metabolic pathways contributing to the energy homeostasis are glycolysis and oxidative phosphorylation, which couple the breakdown of nutrients such as glucose, amino acids and fatty acids to ATP production. The real-time ATP rates were measured following a sequential injection of Oligomycin and Rot/AA using the Seahorse XFe96 Analyzer (Agilent). ATP production rates from glycolysis (glycoATP) were significantly increased in M&#x3c6; exposed to cPE at all time points (6, 24 and 48 hours), while the ATP production rates from mitochondrial respiration (mitoATP) were decreased with significance at 24 and 48 hours (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>). The total ATP production rate of M&#x3c6; exposed to cPE was increased at 6 hours, which was mainly contributed by the glycolytic pathway as the mitoATP showed little change. These results are consistent with the OCR and ECAR results detected under the same conditions (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2</bold>
</xref>, <xref ref-type="fig" rid="f3">
<bold>3</bold>
</xref>), showing that the ATP in M&#x3c6; was mainly derived from glycolysis during challenge with cPE.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>ATP production rates of M&#x3c6; during challenge with cPE. ATP production rates from mitochondrial respiration (mitoATP) and glycolysis (glycoATP) of M&#x3c6; were measured at real-time status following a sequential injection of Oligomycin (1.5 &#x3bc;M) and Rot/AA (0.5 &#x3bc;M) during challenge with cPE or not. Data are shown as mean &#xb1; SEM, <sup>**</sup>
<italic>p</italic> &lt; 0.01, <sup>***</sup>
<italic>p</italic> &lt; 0.001, n.s., no significance. two-tailed unpaired Student&#x2019;s t-tests were compared between control and cPE groups at each time point (n = 10 per each group); One-way ANOVA was used to detect differences within group between time-points.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1199751-g004.tif"/>
</fig>
</sec>
<sec id="s3_4">
<title>Bioenergetic profile of MSC during the challenge of cPE</title>
<p>The crosstalk between M&#x3c6; and MSCs plays a critical role during bone healing (<xref ref-type="bibr" rid="B39">39</xref>). However, the bioenergetic profile of MSCs during inflammation in bone is still obscure. To study the metabolic changes of MSC exposed to cPE, we performed the same Seahorse assays described above using M&#x3c6;. Compared to the control group, MSCs with cPE challenge exhibited little change in OCR, including basal respiration rates and ATP-production coupled respiration rates (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5A, B, D</bold>
</xref>). The maximal respiration and proton leak rates were decreased at 24 hours but showed no significant change at 6 and 48 hours in MSC exposed to cPE (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5C, E</bold>
</xref>).</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Oxygen Consumption Rates (OCR) of MSC during challenge with cPE. <bold>(A)</bold> OCR of MSC were measured with or without cPE at various time points and normalized with cell numbers with consecutive injections of oligomycin (Oligo at 1.5 &#x3bc;M), FCCP (1.5 &#x3bc;M), and Rotenone/antimycin A (0.5 &#x3bc;M). <bold>(B&#x2013;E)</bold> Basal respiration, Maximal respiration, ATP-production coupled respiration and Proton leak rates were presented as bar graphs. Data are shown as mean &#xb1; SEM, <sup>*</sup>
<italic>p</italic> &lt; 0.05, n.s., no significance. two-tailed unpaired Student&#x2019;s t-tests were compared between control and cPE groups at each time point (n = 5 per group of 6 or 24 hours; n = 10 per group of 48 hours); One-way ANOVA was used to detect differences within group between time-points.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1199751-g005.tif"/>
</fig>
<p>Our ECAR results revealed that the glycolytic pathway was significantly enhanced at 24 and 48 hours in MSCs during challenge with cPE (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6A</bold>
</xref>), as the basal glycolysis rates, proton efflux rates (PER) and percentage (%) PER from glycolysis were increased (<xref ref-type="fig" rid="f6">
<bold>Figures&#xa0;6B&#x2013;D</bold>
</xref>). The compensatory glycolysis rates also showed the similar increased levels at 24 and 48 hours in MSC exposed to cPE (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6E</bold>
</xref>).</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Extra Cellular Acidification Rates (ECAR) of MSC during challenge with cPE. <bold>(A)</bold> ECAR of MSC with or without cPE challenge at various time points followed by injections of Rot/AA (0.5 &#x3bc;M), and 2-DG (50 mM) were obtained. <bold>(B&#x2013;E)</bold> Basal glycolysis, Basal proton efflux rate, % PER from glycolysis and Compensatory glycolysis rates were presented as bar graphs. Data are shown as mean &#xb1; SEM, <sup>*</sup>
<italic>p</italic> &lt; 0.05, <sup>**</sup>
<italic>p</italic> &lt; 0.01, <sup>***</sup>
<italic>p</italic> &lt; 0.001, n.s., no significance. two-tailed unpaired Student&#x2019;s t-tests were compared between control and cPE groups at each time point (n = 10 per each group); One-way ANOVA was used to detect differences within group between time-points.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1199751-g006.tif"/>
</fig>
<p>The glycoATP levels were significantly higher in MSCs cPE groups at all time points (6, 24 and 48 hours), and mitoATP levels exhibited little change (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7</bold>
</xref>). The total ATP level showed no significant changes at 6 and 24 hours but was increased at 48 hours in MSC with cPE challenge.</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>ATP production rates of MSC during challenge with cPE. ATP production rates from mitochondrial respiration (mitoATP) and glycolysis (glycoATP) of MSC were measured at real-time status following a sequential injection of Oligomycin (1.5 &#x3bc;M) and Rot/AA (0.5 &#x3bc;M) during challenge with cPE or not. Data are shown as mean &#xb1; SEM, <sup>*</sup>
<italic>p</italic> &lt; 0.05, <sup>**</sup>
<italic>p</italic> &lt; 0.01, <sup>***</sup>
<italic>p</italic> &lt; 0.001, n.s., no significance. two-tailed unpaired Student&#x2019;s t-tests were compared between control and cPE groups at each time point (n=5 per group of 6 or 24 hours; n = 10 per group of 48 hours); One-way ANOVA was used to detect differences within group between time-points.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1199751-g007.tif"/>
</fig>
</sec>
<sec id="s3_5">
<title>M&#x3c6; demonstrated upregulated gene expression of pro-inflammatory cytokines after cPE challenge</title>
<p>To further investigate the metabolic and immunomodulatory changes in M&#x3c6; after cPE challenge, we quantitatively analyzed glycolysis related genes (<italic>Pfkfb3</italic> and <italic>Hif-1&#x3b1;</italic>) and four genes related to the immune properties of M&#x3c6; (<italic>Il-1&#x3b2;, Il-6, Tnf-&#x3b1; and Nos2</italic>). PFKFB3 is a critical regulatory enzyme of glycolysis, as its product Fructose 2,6-bisphosphate (F-2,6-P2), is the most potent allosteric activator of PFK-1, the second one of three rate-limiting enzymes for glycolysis (<xref ref-type="bibr" rid="B40">40</xref>). Glycolysis has been regarded as a cell-intrinsic property and results from the post-translational stabilization of the hypoxia-inducible transcription factor HIF-1 (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>). The qRT-PCR results showed that compared with the control group, the expression levels of <italic>Pfkfb3</italic> and <italic>Hif-1&#x3b1;</italic> were increased (<xref ref-type="fig" rid="f8">
<bold>Figures&#xa0;8A, B</bold>
</xref>), which is consistent with our ECAR results (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). Our result also showed <italic>Pgc-1&#x3b1;</italic>, which regulates mitochondrial biogenesis but also has effects on mitochondrial functions beyond biogenesis (<xref ref-type="bibr" rid="B43">43</xref>), showed a decrease in M&#x3c6; during challenge with cPE (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8C</bold>
</xref>). Nitric Oxide Synthase 2 (Nos2) is another marker of inflammation and enhances macrophage migration and survival (<xref ref-type="bibr" rid="B44">44</xref>). <italic>Nos2</italic> was found to be dramatically increased at 6 hours after cPE challenge (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8G</bold>
</xref>) as well as proinflammatory cytokines of M&#x3c6; (<italic>Il-1&#x3b2;, Il-6, Tnf-&#x3b1;</italic>) (<xref ref-type="fig" rid="f8">
<bold>Figures&#xa0;8D&#x2013;F</bold>
</xref>). Altogether, these results suggest that cPE challenge enhanced the gene expression levels of key glycolytic enzymes and promoted the proinflammatory properties of M&#x3c6;, but impaired the gene expression of <italic>Pgc-1&#x3b1;</italic>, a mitochondrial biogenesis marker.</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>Gene expression levels of mitochondrial metabolism and pro-inflammatory markers in M&#x3c6; during cPE challenge. <bold>(A)</bold> RT-PCR analysis showed that compared with the control group, the expression levels of <italic>Pfkfb3</italic> peaked at 6 hours while the control group remained at a baseline level. <bold>(B)</bold> <italic>Hif-1a</italic> showed increased and peaked at 48 hours with a significant difference. <bold>(C)</bold> <italic>Pgc-1&#x3b1;</italic> showed decreased trend compared to the control group. <bold>(D&#x2013;G)</bold> RT-PCR analysis showed that compared with the control group, the expression levels of pro-inflammatory genes <italic>Il-1&#x3b2;, IL-6, Tnf-a</italic> and <italic>Nos2</italic> in M&#x3c6; during cPE challenge were upregulated and peaked at 6 hours. Data are shown as mean &#xb1; SEM, <sup>*</sup>
<italic>p</italic> &lt; 0.05, <sup>**</sup>
<italic>p</italic> &lt; 0.01, <sup>***</sup>
<italic>p</italic> &lt; 0.001, two-tailed unpaired Student&#x2019;s t-tests were compared between control and cPE groups at each time point (n=3 per each group); One-way ANOVA was used to detect differences within group between time-points.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1199751-g008.tif"/>
</fig>
</sec>
<sec id="s3_6">
<title>MSCs demonstrated upregulation of glycolytic genes after cPE challenge</title>
<p>As the mitochondrial function of MSCs closely correlate with their immunoregulatory properties and differentiation potential, we measured two genes related to mitochondrial metabolism (<italic>Pfkfb3</italic> and <italic>Hif-1a</italic>), one biogenesis marker gene <italic>Pgc-1&#x3b1;</italic> and four genes related to cell differentiation (<italic>Runx2</italic>, <italic>Ocn</italic>, <italic>Opn</italic> and <italic>Fn1</italic>) in MSCs. The expression levels of glycolytic genes <italic>Pfkfb3</italic> and <italic>Hif-1&#x3b1;</italic> were significantly increased in MSCs after cPE challenge compared to the control group (<xref ref-type="fig" rid="f9">
<bold>Figures&#xa0;9A, B</bold>
</xref>), while the mRNA levels of <italic>Pgc-1&#x3b1;</italic> showed no significant changes after cPE challenge at all timepoints (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9C</bold>
</xref>). <italic>Runx2</italic> and <italic>Ocn</italic> showed decreased levels at 24 or 48 hours, respectively in MSC exposed to cPE (<xref ref-type="fig" rid="f9">
<bold>Figures&#xa0;9D, E</bold>
</xref>), while <italic>Opn</italic> and <italic>Fn1</italic> were little changed at all time points (<xref ref-type="fig" rid="f9">
<bold>Figures&#xa0;9F, G</bold>
</xref>). These observations collectively suggested that elevated glycolysis was associated with cPE induced inflammation in MSCs.</p>
<fig id="f9" position="float">
<label>Figure&#xa0;9</label>
<caption>
<p>Gene expression levels of mitochondrial metabolism and differentiation markers in MSC during cPE challenge. <bold>(A, B)</bold> RT-PCR analysis showed that compared with the control group, the expression levels of <italic>Pfkfb3</italic> and <italic>Hif-1a</italic> were increased with significant differences. <bold>(C)</bold> The expression level of <italic>Pgc-1&#x3b1;</italic> showed no difference in MSC during cPE challenge compared to the control group. <bold>(D, E)</bold> <italic>Runx2</italic> and <italic>Ocn</italic> showed a decreased trend after cPE challenge, with a significant difference at 24 and 48 hours, respectively. <bold>(F, G)</bold> The expression levels of <italic>Opn</italic> and <italic>Fn1</italic> in MSC during cPE challenge showed no significant differences compared to the control group. Data are shown as mean &#xb1; SEM, <sup>*</sup>
<italic>p</italic> &lt; 0.05, <sup>**</sup>
<italic>p</italic> &lt; 0.01, <sup>***</sup>
<italic>p</italic> &lt; 0.001, two-tailed unpaired Student&#x2019;s t-tests were compared between control and cPE groups at each time point (n=3 per each group); One-way ANOVA was used to detect differences within group between time-points.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1199751-g009.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Treating dysregulated inflammation-associated bone diseases remains challenging. Deciphering the metabolic reprogramming and mitochondrial dysfunction during inflammation is highly relevant to restoring the important interactions of MSCs and M&#x3c6; in the bone niche. Our goal was to determine the metabolic profile of OXPHOS and glycolysis during inflammation. Our data clearly demonstrate that bone marrow-derived M&#x3c6; and MSCs undergoing glycolytic reprogramming during inflammation induced by the challenge with cPE. M&#x3c6; have elevated glycolytic activity with decreased OXPHOS activity, while MSCs showed increased glycolysis but little change in OXPHOS. In addition, we found that M&#x3c6; and MSCs had more glycoATP but less mitoATP in cPE exposed groups compared to the control groups, which is consistent with the upregulated gene expression of glycolytic enzymes in both M&#x3c6; and MSCs. The mRNA expression level of proinflammatory cytokines (IL1-&#x3b2;, IL-6 and TNF&#x3b1;) dramatically increased in M&#x3c6; after exposure to cPE. Thus, our findings demonstrated the dynamic metabolic changes and mitochondrial function in M&#x3c6; and MSCs during early inflammation induced by the challenge of cPE.</p>
<p>Inflammation is an important biological response to tissue injury, and initiates and modulates the healing process. Different sets of transcription factors are activated during the inflammatory response, including the nuclear factor of the &#x3ba; light chain enhancer of B cells (NF- &#x3ba;B), interferon regulatory factors (IRFs), signal transducers and activators of transcription (STAT) and activator protein1 (AP-1) (<xref ref-type="bibr" rid="B45">45</xref>). Dysregulated inflammation is associated with many skeletal diseases, such as osteolysis, non-union of fractures, and osteoarthritis. To decrease the intensity of persistent inflammation, it is possible to regulate the signaling pathways of proinflammatory transcription factors. NF-&#x3ba;B regulates the synthesis and expression of numerous proinflammatory molecules. We showed that suppression of NF-&#x3ba;B signaling mitigates polyethylene wear particle-induced inflammatory response (<xref ref-type="bibr" rid="B46">46</xref>&#x2013;<xref ref-type="bibr" rid="B50">50</xref>). Although mitochondria are the major organelles for energy production, they also are intimately related to the inflammatory response. For example, specific metabolic pathways are increasingly being recognized as critical hallmarks of macrophage subsets: inflammatory M1 M&#x3c6; display enhanced glycolytic metabolism and reduced mitochondrial activity (<xref ref-type="bibr" rid="B51">51</xref>). Conversely, anti-inflammatory M2 M&#x3c6; show high mitochondrial oxidative phosphorylation (OXPHOS) and are characterized by an enhanced spare respiratory capacity (SRC). Previous studies have demonstrated that oxygen deprivation induced an increase in HIF-1&#x3b1; associated with the activation of glycolytic pathways, leading to an M1 polarization (<xref ref-type="bibr" rid="B52">52</xref>). Therefore, our findings of enhanced glycolysis (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>) and increased <italic>Pfkfb3</italic> and <italic>Hif-1&#x3b1;</italic> levels (<xref ref-type="fig" rid="f8">
<bold>Figures&#xa0;8A, B</bold>
</xref>) imply that M&#x3c6; are polarized to M1 during the challenge of cPE. Moreover, the mitochondrial function can impact innate immunity by affecting the transcriptional regulation of inflammatory cytokines, <italic>via</italic> NF-&#x3ba;B and HIF-1&#x3b1; target inflammatory genes and antiviral type I IFNs genes (<xref ref-type="bibr" rid="B53">53</xref>). Accordingly, our real-time qPCR results (<xref ref-type="fig" rid="f8">
<bold>Figures&#xa0;8D&#x2013;G</bold>
</xref>) showed that the proinflammatory cytokines (IL-1&#x3b2;, IL-6 and TNF&#x3b1;) and the pro-M1 gene Nos2 were increased at the molecular level, which could be the consequence of activated NF-&#x3ba;B and HIF-1&#x3b1; pathways induced by the challenge of cPE. M1 macrophage-related cytokines such as TNF-&#x3b1;, IL-6 and IL-1&#x3b2; inhibit osteogenesis and induce osteoclastogenesis (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>), whereas the M2 macrophage-related cytokines such as IL-4 and IL-10 have the opposite properties and inhibit osteoclastogenesis through the inhibition of NFATc1 (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B57">57</xref>). This suggests that glycolytic reprogramming leads M&#x3c6; to an M1 phenotype and increased proinflammatory cytokines (IL-1&#x3b2;, IL-6 and TNF&#x3b1;) production, which in turn contribute to impaired osteogenesis.</p>
<p>Mitochondrial dysfunction in tissue-specific MSCs plays a critical role in cell fate and the morbidity of acute or chronic inflammation-associated bone diseases. As the most important cells in bone formation and remodeling, tissue resident MSCs were affected by inflammation in every respect, including proliferation, migration, and differentiation (<xref ref-type="bibr" rid="B58">58</xref>). Murphy et&#xa0;al. demonstrated that MSCs isolated from patients with end-stage osteoarthritis (OA) are functionally deficient in terms of <italic>in vitro</italic> proliferation and differentiation (<xref ref-type="bibr" rid="B59">59</xref>). Interestingly, a recent study also identified that chronic inflammation contributes to defective osteogenic differentiation in MSCs by impairing endoplasmic reticulum (ER) function, prolonging ER stress and inducing MORF-mediated-PERK transcription (<xref ref-type="bibr" rid="B60">60</xref>). However, the effects of mitochondrial dysfunction on the immunomodulatory properties of MSCs have not been fully determined. Thus, understanding the bioenergetic and immunological features of MSCs is critical to develop and optimize MSCs-based therapies. In the current study, we investigated the bioenergetic profile and mitochondrial function of MSCs during inflammation induced by cPE. The elevated ECAR with stable OCR in MSCs after cPE challenge (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5</bold>
</xref>, <xref ref-type="fig" rid="f6">
<bold>6</bold>
</xref>) elucidated the metabolic switch and functional adaptions biologically, which further impact the generated immune response and inflammatory status in the context of cell stress.</p>
<p>The question remains of how ECAR is enhanced in MSCs during the challenge of cPE. MSCs are the most promising stem cells for the treatment of inflammatory and immune diseases due to their inherent immunomodulatory properties and self-renewal abilities (<xref ref-type="bibr" rid="B61">61</xref>). In addition to the regulation of proliferation and differentiation, glycolysis is reported to facilitate and maintain MSC immune function (<xref ref-type="bibr" rid="B24">24</xref>). As a signaling molecule regulating glycolysis-associated immunomodulation, Hif-1&#x3b1; played a pivotal role in MSC immunomodulation and metabolism (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B63">63</xref>). Hif-1&#x3b1; overexpressed MSCs promoted expressions of immunosuppressive factors (IDO, COX2 and PD-L1) and secreted more extracellular vesicles (EVs), with better anti-inflammatory therapeutic effects in macrophage polarization (<xref ref-type="bibr" rid="B64">64</xref>). Besides, a previous study suggested that HIF-1&#x3b1; engaged a transcriptional paradigm that shifts cellular bioenergetics toward anaerobic glycolysis (<xref ref-type="bibr" rid="B65">65</xref>). In line with this finding, our qPCR data showed that the gene expression levels of HIF-1&#x3b1; were significantly increased in MSCs after cPE exposure. Thus, the activation of HIF-1&#x3b1; regulatory pathway could be a potential driver in the glycolytic reprogramming to promote MSC&#x2019;s immune function during the challenge of cPE.</p>
<p>Furthermore, Shum et&#xa0;al. demonstrated HIF-1a as a key regulator of MSC energy metabolism during the osteogenic differentiation (<xref ref-type="bibr" rid="B22">22</xref>). While it is dramatically downregulated in osteogenic MSCs, reactivation of HIF-1a led to a significant glycolytic reprogramming and decreased ALP during differentiation. In addition, they found no difference between osteogenic MSCs and the control group regarding the OCR and ECAR index until 14 days later. Our OCR and mitoATP remained stable in both MSCs groups within 48 hours (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5</bold>
</xref>, <xref ref-type="fig" rid="f7">
<bold>7</bold>
</xref>). The qPCR data showed that <italic>Runx2</italic> and <italic>Ocn</italic> was significantly decreased with cPE challenge (<xref ref-type="fig" rid="f9">
<bold>Figures&#xa0;9D, E</bold>
</xref>), while other osteogenic gene markers had little changes (<xref ref-type="fig" rid="f9">
<bold>Figures&#xa0;9F, G</bold>
</xref>). This may be due to the early analysis time for differentiation. Taken together, our findings implied that the challenge of cPE resulted in a preconditioned MSC status with enhanced immune functions, which may compromise the osteogenesis differentiation. The primary genes involved in leading mitochondrial dysfunction during the chronic inflammation at longer time points need to be further revealed in order to provide more insight for future treatment of chronic inflammatory bone healing.</p>
<p>The transcriptional co-activator peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1&#x3b1;) regulates mitochondrial biogenesis and functions including fission, fusion, and mitophagy. PGC-1&#x3b1; has also been characterized as a major factor in the cellular energy metabolism (<xref ref-type="bibr" rid="B66">66</xref>). PGC-1&#x3b1; stimulates mitochondrial biogenesis and promotes the remodeling of metabolically more oxidative and less glycolytic energy production, and participates in the regulation of both carbohydrate and lipid metabolism. Our qPCR data showed the gene expression level of <italic>Pgc-1&#x3b1;</italic> was decreased in M&#x3c6; exposed to cPE (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8C</bold>
</xref>), which is consistent with increased glycolysis and low oxidative phosphorylation as previously reported. This finding suggested that PGC-1&#x3b1; might be a therapeutic candidate of M&#x3c6; for related inflammatory bone disease. Intriguingly, different from M&#x3c6;, our qPCR data of <italic>Pgc-1&#x3b1;</italic> in MSC showed no significant changes during the cPE challenge (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9C</bold>
</xref>). It was reported that PGC-1&#x3b1; was increased in the osteogenically differentiated MSCs and peaked on the 7th day of induction in comparison with undifferentiated MSCs (<xref ref-type="bibr" rid="B67">67</xref>). Moreover, the <italic>in vivo</italic> and <italic>in vitro</italic> experiments showed that deleting PGC-1&#x3b1; suppresses differentiation and activity of osteoblasts, resulting in a significant decrease of cortical thickness and trabecular thickness (<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B68">68</xref>). Our qPCR results showed unchanged mRNA expression levels of <italic>Pgc-1&#x3b1;</italic> (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9C</bold>
</xref>), coupled with the decreased gene expression levels of osteogenic differentiation genes (<italic>Runx2</italic> and <italic>Ocn</italic>) in MSCs exposed to cPE (<xref ref-type="fig" rid="f9">
<bold>Figures&#xa0;9D, E</bold>
</xref>). This may imply that cPE impaired MSC-mediated osteoblastogenesis.</p>
<p>The crosstalk between M&#x3c6; and MSCs plays an important role in the development of skeletal diseases, as well as the maintenance of homeostasis of inflammatory microenvironments. For example, successful fracture healing depends on the coordinated cross-talk between M&#x3c6; and MSCs (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B69">69</xref>). Once the fractures and injured tissue triggered the recruitment of monocytes/macrophages, activated inflammatory M1-like M&#x3c6; were dominant in the early stage to clear cell debris and pathogens <italic>via</italic> pro-inflammatory cytokine release, contributing further to bone regeneration. At the later stages, polarized M2 M&#x3c6; with secreted IL-4 and IL-10 can facilitate bone formation through MSC-mediated osteogenesis, reflecting an essential supporting role of M2 M&#x3c6; in fracture healing (<xref ref-type="bibr" rid="B70">70</xref>). On the other hand, MSCs regulate the function of M&#x3c6; through their immunomodulatory functions in response to an inflammatory microenvironment (<xref ref-type="bibr" rid="B71">71</xref>, <xref ref-type="bibr" rid="B72">72</xref>). However, the exact mechanism of M&#x3c6;-MSC crosstalk in bone healing remains to be determined, particularly under inflammatory microenvironments.</p>
<p>In the present study, we studied M&#x3c6; and MSCs separately to determine whether the observed metabolic reprogramming was due to macrophages or MSCs individually. Studying these 2 cell types together in co-culture using the Seahorse Assay would not discriminate which specific cell type might be responsible for the observed findings. Interestingly, we found that both macrophages and MSCs exhibit glycolytic reprogramming. Thus, it follows that co-cultures of these cells would demonstrate the same phenomenon. In fact, we have performed this co-culture experiment using a 3D model (<xref ref-type="bibr" rid="B30">30</xref>). The results confirmed that glycolytic reprogramming does indeed occur in co-culture of MSCs and M&#x3c6; using comparable techniques including PCR.</p>
<p>There are still several limitations to this study. Firstly, we investigated this <italic>in vitro</italic> study with cPE-induced inflammatory microenvironment based on our well-established chronic inflammatory bone loss mouse model (<xref ref-type="bibr" rid="B32">32</xref>). Longer term analysis is further needed to explore the overall changes regarding osteogenesis and immunomodulation with cPE challenge. Secondly, further analysis is necessary to demonstrate the molecular mechanisms of glycolytic reprogramming and its roles in regulating immunomodulatory properties during inflammation.</p>
</sec>
<sec id="s5" sec-type="conclusion">
<title>Conclusion</title>
<p>We demonstrated the dynamic bioenergetic profiles in M&#x3c6; and MSCs, respectively co-incubated with or without cPE. The Seahorse bioenergetic data showed elevated glycolysis and decreased OXPHOS in M&#x3c6;, while MSCs exposed to cPE showed enhanced glycolysis but unchanged level of OCR. Similarly, upregulated glycolysis related genes <italic>Pfkfb3</italic> and <italic>Hif-1&#x3b1;</italic> were detected in M&#x3c6; and MSCs exposed to cPE. Furthermore, our qPCR data revealed cPE enhanced the gene expression of proinflammatory cytokines and inflammation markers, including <italic>Il-1&#x3b2;, Il-6, Tnf-&#x3b1; and Nos2</italic> in M&#x3c6;. Differentiation related genes <italic>Runx2</italic> and <italic>Ocn</italic> showed decreased gene expression levels in MSC during challenge of cPE.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The animal study was reviewed and approved by Stanford&#x2019;s Administrative Panel on Laboratory Animal Care (APLAC).</p>
</sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>Designed experiments: XL, HS, MZ, QG, SG. Performed experiments: XL, HS, MZ, VT, EH. Data analysis: XL, HS, MZ, NZ. Writing and editing of manuscript: XL, HS, NZ, SC, SG, MZ, VT, QG, MTs, MTo, JK, EH, CM, CC. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>This work was supported by the NIH grants R01AR073145 and R01AR063717 from NIAMS and the Ellenburg Chair in Surgery at Stanford University, James and Kathleen Cornelius Endowed Chair at Michigan State University.</p>
</sec>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsell</surname> <given-names>R</given-names>
</name>
<name>
<surname>Einhorn</surname> <given-names>TA</given-names>
</name>
</person-group>. <article-title>The biology of fracture healing</article-title>. <source>Injury</source> (<year>2011</year>) <volume>42</volume>(<issue>6</issue>):<page-range>551&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.injury.2011.03.031</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wheatley</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Nappo</surname> <given-names>KE</given-names>
</name>
<name>
<surname>Christensen</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Holman</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Brooks</surname> <given-names>DI</given-names>
</name>
<name>
<surname>Potter</surname> <given-names>BK</given-names>
</name>
</person-group>. <article-title>Effect of Nsaids on bone healing rates: A meta-analysis</article-title>. <source>J Am Acad Orthop Surg</source> (<year>2019</year>) <volume>27</volume>(<issue>7</issue>):<page-range>e330&#x2013;e6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5435/JAAOS-D-17-00727</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Recknagel</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bindl</surname> <given-names>R</given-names>
</name>
<name>
<surname>Brochhausen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Gockelmann</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wehner</surname> <given-names>T</given-names>
</name>
<name>
<surname>Schoengraf</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Systemic inflammation induced by a thoracic trauma alters the cellular composition of the early fracture callus</article-title>. <source>J Trauma Acute Care Surg</source> (<year>2013</year>) <volume>74</volume>(<issue>2</issue>):<page-range>531&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/TA.0b013e318278956d</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hurtgen</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>Ward</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Garg</surname> <given-names>K</given-names>
</name>
<name>
<surname>Pollot</surname> <given-names>BE</given-names>
</name>
<name>
<surname>Goldman</surname> <given-names>SM</given-names>
</name>
<name>
<surname>McKinley</surname> <given-names>TO</given-names>
</name>
<etal/>
</person-group>. <article-title>Severe muscle trauma triggers heightened and prolonged local musculoskeletal inflammation and impairs adjacent tibia fracture healing</article-title>. <source>J Musculoskelet Neuronal Interact</source> (<year>2016</year>) <volume>16</volume>(<issue>2</issue>):<page-range>122&#x2013;34</page-range>.</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardy</surname> <given-names>R</given-names>
</name>
<name>
<surname>Cooper</surname> <given-names>MS</given-names>
</name>
</person-group>. <article-title>Bone loss in inflammatory disorders</article-title>. <source>J Endocrinol</source> (<year>2009</year>) <volume>201</volume>(<issue>3</issue>):<page-range>309&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1677/JOE-08-0568</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chow</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Chim</surname> <given-names>YN</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Wong</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Vibration treatment modulates macrophage polarisation and enhances early inflammatory response in Oestrogen-deficient Osteoporotic-fracture healing</article-title>. <source>Eur Cell Mater</source> (<year>2019</year>) <volume>38</volume>:<page-range>228&#x2013;45</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.22203/eCM.v038a16</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chow</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Chim</surname> <given-names>YN</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Wong</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Choy</surname> <given-names>VM</given-names>
</name>
<name>
<surname>Cheung</surname> <given-names>WH</given-names>
</name>
</person-group>. <article-title>Inflammatory response in postmenopausal osteoporotic fracture healing</article-title>. <source>Bone Joint Res</source> (<year>2020</year>) <volume>9</volume>(<issue>7</issue>):<page-range>368&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1302/2046-3758.97.BJR-2019-0300.R2</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodman</surname> <given-names>SB</given-names>
</name>
<name>
<surname>Gallo</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Periprosthetic osteolysis: mechanisms, prevention and treatment</article-title>. <source>J Clin Med</source> (<year>2019</year>) <volume>8</volume>(<issue>12</issue>):<fpage>2091</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/jcm8122091</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname> <given-names>PG</given-names>
</name>
<name>
<surname>Irani</surname> <given-names>A</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>T</given-names>
</name>
<name>
<surname>Biswal</surname> <given-names>S</given-names>
</name>
<name>
<surname>Goodman</surname> <given-names>SB</given-names>
</name>
</person-group>. <article-title>Continuous infusion of uhmwpe particles induces increased bone macrophages and Osteolysis</article-title>. <source>Clin Orthop Relat Res</source> (<year>2011</year>) <volume>469</volume>(<issue>1</issue>):<page-range>113&#x2013;22</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11999-010-1645-5</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narkbunnam</surname> <given-names>R</given-names>
</name>
<name>
<surname>Amanatullah</surname> <given-names>DF</given-names>
</name>
<name>
<surname>Electricwala</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Huddleston</surname> <given-names>JI</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Maloney</surname> <given-names>WJ</given-names>
</name>
<name>
<surname>Goodman</surname> <given-names>SB</given-names>
</name>
</person-group>. <article-title>Outcome of 4 surgical treatments for wear and osteolysis of cementless acetabular components</article-title>. <source>J Arthroplasty</source> (<year>2017</year>) <volume>32</volume>(<issue>9</issue>):<page-range>2799&#x2013;805</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.arth.2017.04.028</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Guilbaud</surname> <given-names>E</given-names>
</name>
<name>
<surname>Tait</surname> <given-names>SWG</given-names>
</name>
<name>
<surname>Yamazaki</surname> <given-names>T</given-names>
</name>
<name>
<surname>Galluzzi</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Mitochondrial control of inflammation</article-title>. <source>Nat Rev Immunol</source> (<year>2022</year>) <volume>23</volume>:<fpage>159</fpage>&#x2013;<lpage>73</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41577-022-00760-x</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corcoran</surname> <given-names>SE</given-names>
</name>
<name>
<surname>O&#x2019;Neill</surname> <given-names>LA</given-names>
</name>
</person-group>. <article-title>Hif1alpha and metabolic reprogramming in inflammation</article-title>. <source>J Clin Invest</source> (<year>2016</year>) <volume>126</volume>(<issue>10</issue>):<page-range>3699&#x2013;707</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI84431</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mills</surname> <given-names>EL</given-names>
</name>
<name>
<surname>Kelly</surname> <given-names>B</given-names>
</name>
<name>
<surname>Logan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Costa</surname> <given-names>ASH</given-names>
</name>
<name>
<surname>Varma</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bryant</surname> <given-names>CE</given-names>
</name>
<etal/>
</person-group>. <article-title>Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages</article-title>. <source>Cell</source> (<year>2016</year>) <volume>167</volume>(<issue>2</issue>):<fpage>457</fpage>&#x2013;<lpage>70 e13</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2016.08.064</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tannahill</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Curtis</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Adamik</surname> <given-names>J</given-names>
</name>
<name>
<surname>Palsson-McDermott</surname> <given-names>EM</given-names>
</name>
<name>
<surname>McGettrick</surname> <given-names>AF</given-names>
</name>
<name>
<surname>Goel</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Succinate is an inflammatory signal that induces Il-1beta through Hif-1alpha</article-title>. <source>Nature</source> (<year>2013</year>) <volume>496</volume>(<issue>7444</issue>):<page-range>238&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature11986</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>W</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Du</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wan</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Mitochondrial complex I activity suppresses inflammation and enhances bone resorption by shifting macrophage-osteoclast polarization</article-title>. <source>Cell Metab</source> (<year>2014</year>) <volume>20</volume>(<issue>3</issue>):<page-range>483&#x2013;98</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cmet.2014.07.011</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fix</surname> <given-names>DK</given-names>
</name>
<name>
<surname>Ekiz</surname> <given-names>HA</given-names>
</name>
<name>
<surname>Petrocelli</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>McKenzie</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Mahmassani</surname> <given-names>ZS</given-names>
</name>
<name>
<surname>O&#x2019;Connell</surname> <given-names>RM</given-names>
</name>
<etal/>
</person-group>. <article-title>Disrupted macrophage metabolic reprogramming in aged soleus muscle during early recovery following disuse atrophy</article-title>. <source>Aging Cell</source> (<year>2021</year>) <volume>20</volume>(<issue>9</issue>):<elocation-id>e13448</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/acel.13448</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keating</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Mesenchymal stromal cells</article-title>. <source>Curr Opin Hematol</source> (<year>2006</year>) <volume>13</volume>(<issue>6</issue>):<page-range>419&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/01.moh.0000245697.54887.6f</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayala-Cuellar</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Jeung</surname> <given-names>EB</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>KC</given-names>
</name>
</person-group>. <article-title>Roles of mesenchymal stem cells in tissue regeneration and immunomodulation</article-title>. <source>Biomol Ther (Seoul)</source> (<year>2019</year>) <volume>27</volume>(<issue>1</issue>):<fpage>25</fpage>&#x2013;<lpage>33</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4062/biomolther.2017.260</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glenn</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Whartenby</surname> <given-names>KA</given-names>
</name>
</person-group>. <article-title>Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy</article-title>. <source>World J Stem Cells</source> (<year>2014</year>) <volume>6</volume>(<issue>5</issue>):<page-range>526&#x2013;39</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4252/wjsc.v6.i5.526</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jorgensen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Khoury</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Musculoskeletal progenitor/stromal cell-derived mitochondria modulate cell differentiation and therapeutical function</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>606781</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.606781</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forni</surname> <given-names>MF</given-names>
</name>
<name>
<surname>Peloggia</surname> <given-names>J</given-names>
</name>
<name>
<surname>Trudeau</surname> <given-names>K</given-names>
</name>
<name>
<surname>Shirihai</surname> <given-names>O</given-names>
</name>
<name>
<surname>Kowaltowski</surname> <given-names>AJ</given-names>
</name>
</person-group>. <article-title>Murine mesenchymal stem cell commitment to differentiation is regulated by mitochondrial dynamics</article-title>. <source>Stem Cells</source> (<year>2016</year>) <volume>34</volume>(<issue>3</issue>):<page-range>743&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/stem.2248</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shum</surname> <given-names>LC</given-names>
</name>
<name>
<surname>White</surname> <given-names>NS</given-names>
</name>
<name>
<surname>Mills</surname> <given-names>BN</given-names>
</name>
<name>
<surname>Bentley</surname> <given-names>KL</given-names>
</name>
<name>
<surname>Eliseev</surname> <given-names>RA</given-names>
</name>
</person-group>. <article-title>Energy metabolism in mesenchymal stem cells during osteogenic differentiation</article-title>. <source>Stem Cells Dev</source> (<year>2016</year>) <volume>25</volume>(<issue>2</issue>):<page-range>114&#x2013;22</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/scd.2015.0193</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baker</surname> <given-names>N</given-names>
</name>
<name>
<surname>Boyette</surname> <given-names>LB</given-names>
</name>
<name>
<surname>Tuan</surname> <given-names>RS</given-names>
</name>
</person-group>. <article-title>Characterization of bone marrow-derived mesenchymal stem cells in aging</article-title>. <source>Bone</source> (<year>2015</year>) <volume>70</volume>:<fpage>37</fpage>&#x2013;<lpage>47</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bone.2014.10.014</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>H</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Immunomodulatory properties of mesenchymal stromal/stem cells: the link with metabolism</article-title>. <source>J Adv Res</source> (<year>2023</year>) <volume>45</volume>:<fpage>15</fpage>&#x2013;<lpage>29</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jare.2022.05.012</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Contreras-Lopez</surname> <given-names>R</given-names>
</name>
<name>
<surname>Elizondo-Vega</surname> <given-names>R</given-names>
</name>
<name>
<surname>Paredes</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Luque-Campos</surname> <given-names>N</given-names>
</name>
<name>
<surname>Torres</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Tejedor</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Hif1alpha-dependent metabolic reprogramming governs mesenchymal stem/stromal cell immunoregulatory functions</article-title>. <source>FASEB J</source> (<year>2020</year>) <volume>34</volume>(<issue>6</issue>):<page-range>8250&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1096/fj.201902232R</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nich</surname> <given-names>C</given-names>
</name>
<name>
<surname>Takakubo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Pajarinen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ainola</surname> <given-names>M</given-names>
</name>
<name>
<surname>Salem</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sillat</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophages-key cells in the response to wear debris from joint replacements</article-title>. <source>J BioMed Mater Res A</source> (<year>2013</year>) <volume>101</volume>(<issue>10</issue>):<page-range>3033&#x2013;45</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jbm.a.34599</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodman</surname> <given-names>SB</given-names>
</name>
<name>
<surname>Gibon</surname> <given-names>E</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>The basic science of periprosthetic osteolysis</article-title>. <source>Instr Course Lect</source> (<year>2013</year>) <volume>62</volume>:<page-range>201&#x2013;6</page-range>.</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Purdue</surname> <given-names>PE</given-names>
</name>
</person-group>. <article-title>Alternative macrophage activation in periprosthetic osteolysis</article-title>. <source>Autoimmunity</source> (<year>2008</year>) <volume>41</volume>(<issue>3</issue>):<page-range>212&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/08916930701694626</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ingham</surname> <given-names>E</given-names>
</name>
<name>
<surname>Fisher</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>The role of macrophages in osteolysis of total joint replacement</article-title>. <source>Biomaterials</source> (<year>2005</year>) <volume>26</volume>(<issue>11</issue>):<page-range>1271&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biomaterials.2004.04.035</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teissier</surname> <given-names>V</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>EE</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabolic profile of mesenchymal stromal cells and macrophages in the presence of polyethylene particles in a 3d model</article-title>. <source>Stem Cell Res Ther</source> (<year>2023</year>) <volume>14</volume>(<issue>1</issue>):<fpage>99</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13287-023-03260-4</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kushioka</surname> <given-names>J</given-names>
</name>
<name>
<surname>Toya</surname> <given-names>M</given-names>
</name>
<name>
<surname>Utsunomiya</surname> <given-names>T</given-names>
</name>
<name>
<surname>Hirata</surname> <given-names>H</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>EE</given-names>
</name>
<etal/>
</person-group>. <article-title>Sex differences in the therapeutic effect of unaltered versus nfkappab sensing Il-4 over-expressing mesenchymal stromal cells in a murine model of chronic inflammatory bone loss</article-title>. <source>Front Bioeng Biotechnol</source> (<year>2022</year>) <volume>10</volume>:<elocation-id>962114</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fbioe.2022.962114</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Utsunomiya</surname> <given-names>T</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kohno</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ueno</surname> <given-names>M</given-names>
</name>
<name>
<surname>Maruyama</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Mesenchymal stem cells and Nf-kappab sensing interleukin-4 over-expressing mesenchymal stem cells are equally effective in mitigating particle-associated chronic inflammatory bone loss in mice</article-title>. <source>Front Cell Dev Biol</source> (<year>2021</year>) <volume>9</volume>:<elocation-id>757830</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcell.2021.757830</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kohno</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Romero-Lopez</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pajarinen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Maruyama</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Nf&#x3ba;b sensing Il-4 secreting mesenchymal stem cells mitigate the proinflammatory response of macrophages exposed to polyethylene wear particles</article-title>. <source>J BioMed Mater Res A</source> (<year>2018</year>) <volume>106</volume>(<issue>10</issue>):<page-range>2744&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jbm.a.36504</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Utsunomiya</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kohno</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ueno</surname> <given-names>M</given-names>
</name>
<name>
<surname>Maruyama</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Suppression of Nf-Kb-induced chronic inflammation mitigates inflammatory osteolysis in the murine continuous polyethylene particle infusion model</article-title>. <source>J BioMed Mater Res A</source> (<year>2021</year>) <volume>109</volume>(<issue>10</issue>):<page-range>1828&#x2013;39</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jbm.a.37175</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nathan</surname> <given-names>K</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>LY</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>T</given-names>
</name>
<name>
<surname>Pajarinen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jamsen</surname> <given-names>E</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>JF</given-names>
</name>
<etal/>
</person-group>. <article-title>Precise immunomodulation of the M1 to M2 macrophage transition enhances mesenchymal stem cell osteogenesis and differs by sex</article-title>. <source>Bone Joint Res</source> (<year>2019</year>) <volume>8</volume>(<issue>10</issue>):<page-range>481&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1302/2046-3758.810.BJR-2018-0231.R2</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weischenfeldt</surname> <given-names>J</given-names>
</name>
<name>
<surname>Porse</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Bone marrow-derived macrophages (Bmm): isolation and applications</article-title>. <source>CSH Protoc</source> (<year>2008</year>) <volume>2008</volume>:<page-range>pdb.prot5080</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/pdb.prot5080</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenfield</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Beidelschies</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Tatro</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Goldberg</surname> <given-names>VM</given-names>
</name>
<name>
<surname>Hise</surname> <given-names>AG</given-names>
</name>
</person-group>. <article-title>Bacterial pathogen-associated molecular patterns stimulate biological activity of orthopaedic wear particles by activating cognate toll-like receptors</article-title>. <source>J Biol Chem</source> (<year>2010</year>) <volume>285</volume>(<issue>42</issue>):<page-range>32378&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M110.136895</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mookerjee</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Brand</surname> <given-names>MD</given-names>
</name>
</person-group>. <article-title>Measurement and analysis of extracellular acid production to determine glycolytic rate</article-title>. <source>J Vis Exp</source> (<year>2015</year>) <volume>106)</volume>:<elocation-id>e53464</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3791/53464</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pajarinen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>T</given-names>
</name>
<name>
<surname>Gibon</surname> <given-names>E</given-names>
</name>
<name>
<surname>Kohno</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Maruyama</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nathan</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Mesenchymal stem cell-macrophage crosstalk and bone healing</article-title>. <source>Biomaterials</source> (<year>2019</year>) <volume>196</volume>:<page-range>80&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.12.025</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rider</surname> <given-names>MH</given-names>
</name>
<name>
<surname>Bertrand</surname> <given-names>L</given-names>
</name>
<name>
<surname>Vertommen</surname> <given-names>D</given-names>
</name>
<name>
<surname>Michels</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Rousseau</surname> <given-names>GG</given-names>
</name>
<name>
<surname>Hue</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis</article-title>. <source>Biochem J</source> (<year>2004</year>) <volume>381</volume>(<issue>Pt 3</issue>):<page-range>561&#x2013;79</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1042/BJ20040752</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pouyssegur</surname> <given-names>J</given-names>
</name>
<name>
<surname>Dayan</surname> <given-names>F</given-names>
</name>
<name>
<surname>Mazure</surname> <given-names>NM</given-names>
</name>
</person-group>. <article-title>Hypoxia signalling in cancer and approaches to enforce tumour regression</article-title>. <source>Nature</source> (<year>2006</year>) <volume>441</volume>(<issue>7092</issue>):<page-range>437&#x2013;43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature04871</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Semenza</surname> <given-names>GL</given-names>
</name>
</person-group>. <article-title>Targeting Hif-1 for cancer therapy</article-title>. <source>Nat Rev Cancer</source> (<year>2003</year>) <volume>3</volume>(<issue>10</issue>):<page-range>721&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrc1187</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halling</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Pilegaard</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Pgc-1alpha-mediated regulation of mitochondrial function and physiological implications</article-title>. <source>Appl Physiol Nutr Metab</source> (<year>2020</year>) <volume>45</volume>(<issue>9</issue>):<page-range>927&#x2013;36</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1139/apnm-2020-0005</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Gray</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Willette-Brown</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>G</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>Q</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage inducible nitric oxide synthase circulates inflammation and promotes lung carcinogenesis</article-title>. <source>Cell Death Discov</source> (<year>2018</year>) <volume>4</volume>:<elocation-id>46</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41420-018-0046-5</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smale</surname> <given-names>ST</given-names>
</name>
<name>
<surname>Natoli</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Transcriptional control of inflammatory responses</article-title>. <source>Cold Spring Harb Perspect Biol</source> (<year>2014</year>) <volume>6</volume>(<issue>11</issue>):<elocation-id>a016261</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/cshperspect.a016261</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Utsunomiya</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kohno</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ueno</surname> <given-names>M</given-names>
</name>
<name>
<surname>Maruyama</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Suppression of Nf-kappab-induced chronic inflammation mitigates inflammatory osteolysis in the murine continuous polyethylene particle infusion model</article-title>. <source>J BioMed Mater Res A</source> (<year>2021</year>) <volume>109</volume>(<issue>10</issue>):<page-range>1828&#x2013;39</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jbm.a.37175</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname> <given-names>TH</given-names>
</name>
<name>
<surname>Pajarinen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sato</surname> <given-names>T</given-names>
</name>
<name>
<surname>Loi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>C</given-names>
</name>
<name>
<surname>Cordova</surname> <given-names>LA</given-names>
</name>
<etal/>
</person-group>. <article-title>Nf-kappab decoy oligodeoxynucleotide mitigates wear particle-associated bone loss in the murine continuous infusion model</article-title>. <source>Acta Biomater</source> (<year>2016</year>) <volume>41</volume>:<page-range>273&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.actbio.2016.05.038</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sato</surname> <given-names>T</given-names>
</name>
<name>
<surname>Pajarinen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>TH</given-names>
</name>
<name>
<surname>Tamaki</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Loi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Egashira</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Nf-kappab decoy oligodeoxynucleotide inhibits wear particle-induced inflammation in a murine calvarial model</article-title>. <source>J BioMed Mater Res A</source> (<year>2015</year>) <volume>103</volume>(<issue>12</issue>):<page-range>3872&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jbm.a.35532</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname> <given-names>TH</given-names>
</name>
<name>
<surname>Goodman</surname> <given-names>SB</given-names>
</name>
</person-group>. <article-title>Suppression of Nf-kappab signaling mitigates polyethylene wear particle-induced inflammatory response</article-title>. <source>Inflamm Cell Signal</source> (<year>2014</year>) <volume>1</volume>(<issue>4</issue>):<elocation-id>e223</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.14800/ics.223</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname> <given-names>TH</given-names>
</name>
<name>
<surname>Tamaki</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Pajarinen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Waters</surname> <given-names>HA</given-names>
</name>
<name>
<surname>Woo</surname> <given-names>DK</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Chronic inflammation in biomaterial-induced periprosthetic osteolysis: Nf-kappab as a therapeutic target</article-title>. <source>Acta Biomater</source> (<year>2014</year>) <volume>10</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>10</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.actbio.2013.09.034</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van den Bossche</surname> <given-names>J</given-names>
</name>
<name>
<surname>Baardman</surname> <given-names>J</given-names>
</name>
<name>
<surname>de Winther</surname> <given-names>MP</given-names>
</name>
</person-group>. <article-title>Metabolic characterization of polarized M1 and M2 bone marrow-derived macrophages using real-time extracellular flux analysis</article-title>. <source>J Vis Exp</source> (<year>2015</year>) <volume>105</volume>(<issue>105</issue>):<fpage>53424</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3791/53424</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Planat-Benard</surname> <given-names>V</given-names>
</name>
<name>
<surname>Varin</surname> <given-names>A</given-names>
</name>
<name>
<surname>Casteilla</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Mscs and inflammatory cells crosstalk in regenerative medicine: concerted actions for optimized resolution driven by energy metabolism</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>626755</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.626755</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monlun</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hyernard</surname> <given-names>C</given-names>
</name>
<name>
<surname>Blanco</surname> <given-names>P</given-names>
</name>
<name>
<surname>Lartigue</surname> <given-names>L</given-names>
</name>
<name>
<surname>Faustin</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Mitochondria as molecular platforms integrating multiple innate immune signalings</article-title>. <source>J Mol Biol</source> (<year>2017</year>) <volume>429</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>13</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jmb.2016.10.028</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>The macrophage-osteoclast axis in osteoimmunity and osteo-related diseases</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>664871</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.664871</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Cordova</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Pajarinen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>TH</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Goodman</surname> <given-names>SB</given-names>
</name>
</person-group>. <article-title>Inflammation, fracture and bone repair</article-title>. <source>Bone</source> (<year>2016</year>) <volume>86</volume>:<page-range>119&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bone.2016.02.020</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakashima</surname> <given-names>T</given-names>
</name>
<name>
<surname>Hayashi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Takayanagi</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>New insights into osteoclastogenic signaling mechanisms</article-title>. <source>Trends Endocrinol Metab</source> (<year>2012</year>) <volume>23</volume>(<issue>11</issue>):<page-range>582&#x2013;90</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.tem.2012.05.005</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takayanagi</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems</article-title>. <source>Nat Rev Immunol</source> (<year>2007</year>) <volume>7</volume>(<issue>4</issue>):<fpage>292</fpage>&#x2013;<lpage>304</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri2062</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhai</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Fei</surname> <given-names>D</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>X</given-names>
</name>
<name>
<surname>He</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Nanorepairers rescue inflammation-induced mitochondrial dysfunction in mesenchymal stem cells</article-title>. <source>Adv Sci (Weinh)</source> (<year>2022</year>) <volume>9</volume>(<issue>4</issue>):<elocation-id>e2103839</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/advs.202103839</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Dixon</surname> <given-names>K</given-names>
</name>
<name>
<surname>Beck</surname> <given-names>S</given-names>
</name>
<name>
<surname>Fabian</surname> <given-names>D</given-names>
</name>
<name>
<surname>Feldman</surname> <given-names>A</given-names>
</name>
<name>
<surname>Barry</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis</article-title>. <source>Arthritis Rheum</source> (<year>2002</year>) <volume>46</volume>(<issue>3</issue>):<page-range>704&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/art.10118</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname> <given-names>P</given-names>
</name>
<name>
<surname>Li</surname> <given-names>B</given-names>
</name>
<name>
<surname>An</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>J</given-names>
</name>
<name>
<surname>He</surname> <given-names>X</given-names>
</name>
<name>
<surname>Hou</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Decreased Morf leads to prolonged endoplasmic reticulum stress in periodontitis-associated chronic inflammation</article-title>. <source>Cell Death Differ</source> (<year>2016</year>) <volume>23</volume>(<issue>11</issue>):<page-range>1862&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cdd.2016.74</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname> <given-names>N</given-names>
</name>
<name>
<surname>Scholtemeijer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shah</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential</article-title>. <source>Trends Pharmacol Sci</source> (<year>2020</year>) <volume>41</volume>(<issue>9</issue>):<page-range>653&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.tips.2020.06.009</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-King</surname> <given-names>H</given-names>
</name>
<name>
<surname>Garcia</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Ontoria-Oviedo</surname> <given-names>I</given-names>
</name>
<name>
<surname>Ciria</surname> <given-names>M</given-names>
</name>
<name>
<surname>Montero</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Sepulveda</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Hypoxia inducible factor-1alpha potentiates jagged 1-mediated angiogenesis by mesenchymal stem cell-derived exosomes</article-title>. <source>Stem Cells</source> (<year>2017</year>) <volume>35</volume>(<issue>7</issue>):<page-range>1747&#x2013;59</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/stem.2618</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez</surname> <given-names>VG</given-names>
</name>
<name>
<surname>Ontoria-Oviedo</surname> <given-names>I</given-names>
</name>
<name>
<surname>Ricardo</surname> <given-names>CP</given-names>
</name>
<name>
<surname>Harding</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Sacedon</surname> <given-names>R</given-names>
</name>
<name>
<surname>Varas</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Overexpression of hypoxia-inducible factor 1 alpha improves immunomodulation by dental mesenchymal stem cells</article-title>. <source>Stem Cell Res Ther</source> (<year>2017</year>) <volume>8</volume>(<issue>1</issue>):<fpage>208</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13287-017-0659-2</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomez-Ferrer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Villanueva-Badenas</surname> <given-names>E</given-names>
</name>
<name>
<surname>Sanchez-Sanchez</surname> <given-names>R</given-names>
</name>
<name>
<surname>Sanchez-Lopez</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Baquero</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Sepulveda</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Hif-1alpha and pro-inflammatory signaling improves the immunomodulatory activity of Msc-derived extracellular vesicles</article-title>. <source>Int J Mol Sci</source> (<year>2021</year>) <volume>22</volume>(<issue>7</issue>):<fpage>3416</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms22073416</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Semenza</surname> <given-names>GL</given-names>
</name>
</person-group>. <article-title>Life with oxygen</article-title>. <source>Science</source> (<year>2007</year>) <volume>318</volume>(<issue>5847</issue>):<page-range>62&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.1147949</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ward</surname> <given-names>WF</given-names>
</name>
</person-group>. <article-title>Pgc-1alpha: A key regulator of energy metabolism</article-title>. <source>Adv Physiol Educ</source> (<year>2006</year>) <volume>30</volume>(<issue>4</issue>):<page-range>145&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/advan.00052.2006</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>CT</given-names>
</name>
<name>
<surname>Shih</surname> <given-names>YR</given-names>
</name>
<name>
<surname>Kuo</surname> <given-names>TK</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>OK</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>YH</given-names>
</name>
</person-group>. <article-title>Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells</article-title>. <source>Stem Cells</source> (<year>2008</year>) <volume>26</volume>(<issue>4</issue>):<page-range>960&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1634/stemcells.2007-0509</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colaianni</surname> <given-names>G</given-names>
</name>
<name>
<surname>Lippo</surname> <given-names>L</given-names>
</name>
<name>
<surname>Sanesi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Brunetti</surname> <given-names>G</given-names>
</name>
<name>
<surname>Celi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cirulli</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Deletion of the transcription factor Pgc-1alpha in mice negatively regulates bone mass</article-title>. <source>Calcif Tissue Int</source> (<year>2018</year>) <volume>103</volume>(<issue>6</issue>):<page-range>638&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00223-018-0459-4</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Gardner</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Vyas</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ishida</surname> <given-names>R</given-names>
</name>
<name>
<surname>Tawfik</surname> <given-names>VL</given-names>
</name>
</person-group>. <article-title>Modeling complex orthopedic trauma in rodents: bone, muscle and nerve injury and healing</article-title>. <source>Front Pharmacol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>620485</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2020.620485</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schlundt</surname> <given-names>C</given-names>
</name>
<name>
<surname>El Khassawna</surname> <given-names>T</given-names>
</name>
<name>
<surname>Serra</surname> <given-names>A</given-names>
</name>
<name>
<surname>Dienelt</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wendler</surname> <given-names>S</given-names>
</name>
<name>
<surname>Schell</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophages in bone fracture healing: their essential role in endochondral ossification</article-title>. <source>Bone</source> (<year>2018</year>) <volume>106</volume>:<fpage>78</fpage>&#x2013;<lpage>89</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bone.2015.10.019</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uccelli</surname> <given-names>A</given-names>
</name>
<name>
<surname>Moretta</surname> <given-names>L</given-names>
</name>
<name>
<surname>Pistoia</surname> <given-names>V</given-names>
</name>
</person-group>. <article-title>Mesenchymal stem cells in health and disease</article-title>. <source>Nat Rev Immunol</source> (<year>2008</year>) <volume>8</volume>(<issue>9</issue>):<page-range>726&#x2013;36</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri2395</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nauta</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Fibbe</surname> <given-names>WE</given-names>
</name>
</person-group>. <article-title>Immunomodulatory properties of mesenchymal stromal cells</article-title>. <source>Blood</source> (<year>2007</year>) <volume>110</volume>(<issue>10</issue>):<page-range>3499&#x2013;506</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood-2007-02-069716</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>